Site-Specific Antibody Conjugation for ADC and Beyond
AbstractAntibody-drug conjugates (ADCs) have become a promising class of antitumor agents with four conjugates being approved by regulatory agencies for treating cancer patients. To improve the conventional conjugations that are currently applied to generate these heterogeneous products, various site-specific approaches have been developed. These methods couple cytotoxins or chemotherapeutic drugs to specifically defined sites in antibody molecules including cysteine, glutamine, unnatural amino acids, short peptide tags, and glycans. The ADCs produced showed high homogeneity, increased therapeutic index, and strong antitumor activities in vitro and in vivo. Moreover, there are recent trends in using these next generation technologies beyond the cytotoxin-conjugated ADC. These site-specific conjugations have been applied for the generation of many different immunoconjugates including bispecific Fab or small molecule–antibody conjugates, immunosuppressive antibodies, and antibody–antibiotic conjugates. Thus, it is likely that additional technologies and related site-specific conjugates will emerge in the near future, with various chemicals or small molecular weight proteins in addition to cytotoxin for better treatment of many challenging diseases. View Full-Text
Share & Cite This Article
Zhou, Q. Site-Specific Antibody Conjugation for ADC and Beyond. Biomedicines 2017, 5, 64.
Zhou Q. Site-Specific Antibody Conjugation for ADC and Beyond. Biomedicines. 2017; 5(4):64.Chicago/Turabian Style
Zhou, Qun. 2017. "Site-Specific Antibody Conjugation for ADC and Beyond." Biomedicines 5, no. 4: 64.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.